Kornimate/medical-research-clean huggingface dataset:
a study to evaluate rist4721 in hidradenitis suppurativa (hs)

Conditions: Hidradenitis Suppurativa

Summary: a randomized, double-blinded, placebo-controlled, phase 2a study to evaluate the efficacy and safety of rist4721 in subjects with hidradenitis suppurativa


Eligibility criteria:
inclusion criteria: * diagnosis of hs for at least 1 year prior to screening * hs lesions must be present in at least 2 distinct anatomic areas * a total an count (sum of abscesses and inflammatory nodules) \> 6 across all anatomical sites at both the screening and baseline visits * willing to use contraception for the duration of the study exclusion criteria: * presence of other skin conditions which may interfere with study assessments * presence of active, chronic or latent bacterial, viral, fungal mycobacterial infection (including latent tb) or history of infection within 4 weeks of screening * body mass index (bmi) \>48kg/m2 * breastfeeding or pregnant
prednisolone vs. ciclosporine in severe atopic eczema

Conditions: Atopic Dermatitis

Summary: to investigate the comparative efficacy of ciclosporine a and prednisolone in adult patients with severe atopic dermatitis.


Eligibility criteria:
inclusion criteria: * male and female patients age \>= 18 and \< 55 * weight between 50 and 100 kg * confirmed diagnosis of ae (uk working party criteria) * objective scorad \> 40 * dlqi \> 10 * resistancy against topical treatment options including steroids and calcineurin-inhibitors exclusion criteria: * participation to another clinical trial within the last 4 weeks before baseline * pregnant or breastfeeding * women of childbearing potential without adequate contraception * allergy against prednisolone or ciclosporine a * acute bacterial or viral infection * malignant tumor in personal history * diabetes mellitus * arterial hypertension * glaucoma * peptic ulcer * severe osteoporosis * tuberculosis in personal history * colitis ulcerosa * diverticulitis * concurrent treatment with chloroquin, mefloquin, statins, warafin * creatinin clearance \< 60 ml /min * uv treatment within 8 weeks before inclusion * ongoing systemic immunosuppressive treatment * planned vaccination within 8 weeks before study entry, during study and 2 weeks after end of study * poliomyelitis * lymphadenitis after bcg vaccination * hyperuricaemia * chronic liver disease * xeroderma pigmentosum, cockaye-syndrome, bloom syndrome * psychiatric co-morbidity * drug or alcohol abuse

Keywords: atopic dermatitis prednisolone ciclosporine scorad dlqi qaly wlq
weekly docetaxel/irinotecan for non-resectable gastric cancers after cisplatin plus 5-fu/leucovorin

Conditions: Gastric Cancer

Summary: in this study, the investigators will use p-hdfl, a regimen with high tumor remission rate (\~ 60-70%) and with only modest treatment-associated toxicities, as induction chemotherapy for patients with non-resectable gastric cancer. for those patients who have achieved complete response (cr) or partial response (pr), di will be used to "consolidate" the remission. for those patients who fail to achieve remission by p-hdfl, di will be used as salvage chemotherapy. the efficacy and toxicities of di in these two settings will be evaluated in this prospective study.

1. to evaluate if weekly docetaxel-irinotecan,a potentially non-cross-resistant regimen,can prolong the overall survival (os) or the duration of remission in those patients who have achieved cr or pr by p-hdfl regimen 2. to evaluate the efficacy of weekly docetaxel-irinotecan combination as salvage regimen for those patients who have either failed to achieve remission or have recurred from p-hdfl chemotherapy 3. to find out the optimal doses for docetaxel and irinotecan in a weekly dosing schedule for gastric cancer patients 4. to evaluate the toxicities of weekly docetaxel-irinotecan regimen in inoperable gastric cancers

Eligibility criteria:
inclusion criteria: 1. histologically or cytologically confirmed gastric adenocarcinoma 2. measurable or evaluable disease 3. no previous c/t 4. age 16 \~ 75 years 5. karnofsky performance status of 60% 6. 4 weeks after r/t 7. adjuvant c/t: the last dosing of c/t 6 months before enrollment 8. wbc \>= 4,000, platelets \>= 100k, creatinine \ 70mg/dl exclusion criteria: 1. cns metastasis 2. patients receive concomitant anti-cancer c/t or r/t 3. patients who are pregnant and with an expected life expectancy less than 3 months 4. symptomatic heart disease, active infection, extensive liver disease, or liver cirrhosis

Keywords: combination, chemotherapy, inoperable gastric cancer
snacks and satiety

Conditions: Eating Behavior; Overweight; Obesity

Summary: this study is designed to compare two types of snacks (almonds or a cereal-based snack), eaten between meals, on measures of appetite, including appetitive hormones, self-reported feelings of hunger and fullness, and food intake at a buffet meal or in the home environment. the investigators hypothesize that the acute responses of appetitive hormones to a meal challenge protocol will differ between almond and cereal-based snacks based on multivariate models of satiety that will be predictive of ad libitum food intake at a dinner meal as part of the meal challenge protocol. further, the investigators will estimate if, under free-living conditions, self-selected and self-reported food intake will show appropriate energy compensation for the added calories of the snacks, and determine if one type of snack is superior to the other in this regard.

this study will use a randomized, parallel design that includes an almond snack intervention and a cereal-based snack intervention group. the almond intervention will be roasted, unsalted almonds at a level of 56 grams per day for 4 weeks. the cereal-based intervention will be isocaloric snacks provided in the form of a mixture of dry cereal, pretzels, and bread sticks for 4 weeks. a satiety test protocol will be done at the beginning and the end of the intervention period. each test day will include measures of satiety responses to two standard meals, two snacks (either almonds or cereal-based snacks), and a dinner buffet. the protocol to evaluate satiety signals include tonic measures that may signal homeostasis to the brain and evaluation of episodic signals that may drive food intake in addition, other modulators of satiety will be tested including evaluation of preferences for palatable foods, self-reports of cravings and satiety using questionnaires, and perceived hunger, fullness, desire to eat.

Eligibility criteria:
inclusion criteria: * pre-menopausal * body mass index 25 - 39.9 kg/m2 exclusion criteria: * women who are post-menopausal or peri-menopausal * bmi \ 40 kg/m2 * allergies to tree nuts * using any hormonal contraception including oral contraceptive, contraceptive patch, contraceptive ring, contraceptive injection (e.g. depo-provera), or contraceptive implant (e.g. nexplanon/implanon) * menstrual cycle lengths \ 45 days, or have amenorrhea, eumenorrhea, or polymenorrhea. * pregnant or nursing within the last 6 months, or plan to become pregnant during the trial * medical diagnoses of chronic diseases including cardiovascular or pulmonary diseases, renal disease, cancer, type 1 or type 2 diabetes mellitus, thyroid disease requiring medication, inflammatory bowel disease, irritable bowel disease, or those with recent major surgeries * current medical diagnosis of polycystic ovarian syndrome (pcos).

Keywords: satiety gastrointestinal hormones appetite dietary fiber food cravings
evaluating the impact of social music

Conditions: Mental Health Issue; COVID-19

Summary: mental health vulnerability due to stress is increased in people of african descent (pads) in america due to disproportionate effects of racism, poverty, education, and criminal justice sentencing. various meditation and mindfulness approaches have provided evidence of measured reductions in multiple negative dimensions of stress. however, the majority of these studies do not have an adequate representation of pads or other marginalized groups and are not designed to be culturally relevant or community based. music has been shown to alleviate multiple symptoms of stress and has been shown to be a preferred and effective support for meditation and mindfulness. however, its role in stress management in pads engaged in meditation or mindfulness is seldom studied. this study aims to evaluate the effects of a virtual, community-based music mindfulness program on stress management in pad community members with anxiety and depression during covid19. 2b. social music study: investigators will assess the neural mechanisms of feelings of subjective connectedness during communal music listening and creating between dyads of subjects who are both familiar and unfamiliar with each other.

the investigators also propose a study to investigate the effects of communal drumming in reducing anxiety and increasing connectedness within drum circle community. investigators hypothesize that these intervention will lead to reductions in scores on stress scales and will provide preliminary data for studies evaluating these types of community programs as an adjunct to the standard of care. participants will be screened, consented, and enrolled in dyads in a paradigm in which they will be positioned across from each other while listening to various types of music (i.e. music that is harmonically-intact and music in which the harmonic content has been randomly scrambled). survey data will also be collected to assess variables such as musical experience, partner familiarity, perceived stress, etc.

Eligibility criteria:
inclusion criteria: * ages 16 and older exclusion criteria: * contraindications to functional near infrared spectroscopy or electroencephalography * ages 15 and younger

Keywords: mindfulness meditation music
leg exercise during ecmo

Conditions: Refractory Respiratory Failure

Summary: patients undergoing extracorporeal membrane oxygenation (ecmo) are at high risk for deconditioning and functional decline. the primary aim of this study is to assess the functional impact of leg exercise during the pre-ambulation phase in patients undergoing ecmo.

the investigators are conducting this study to explore the impact of closed-chain leg exercise in individuals undergoing ecmo. aim 1: to determine if closed-chain leg exercise decreases the time to initial ambulation. the investgators hypothesize that adding leg exercise will decrease time to ambulation. aim 2: to determine the impact of closed chain leg exercise on functional ability. the investigators hypothesize that adding leg exercise will improve functional outcomes when added to an existing early mobilization program. aim 3: to determine the effect of closed chain leg exercise on hospital outcomes. the investigators hypothesize that hospital related outcomes will improve when leg exercise is added to an existing early mobilization program.

Eligibility criteria:
inclusion criteria: * patients with refractory respiratory failure undergoing ecmo at the university of minnesota medical center, fairview. * able to follow 3 out of 3 one-step commands via protocol. * active inpatient physical therapy referral. * ecmo delivery is veno-venous with internal jugular catheter. exclusion criteria: * femoral catheter of any kind present * veno-arterial ecmo set-up * sedation such that self-consent is not attainable * medical instability, as determined by primary critical care physician
sevoflurane and dexmedetomidine's contrasting renal impacts after non-cardiac surgery

Conditions: AKI - Acute Kidney Injury

Summary: postoperative acute kidney injury (po-aki) is a significant complication, especially after complex surgeries. the choice of anesthetic may influence po-aki risk. while sevoflurane (sevo) has been associated with potential renal risks, dexmedetomidine (dxm) has demonstrated renoprotective effects in various surgical settings. these protective effects may be linked to dxm's immunomodulatory properties and influence on the redox balance. given the common use of sevo in major non-cardiac surgery and the potential for renal vulnerability, particularly in the elderly, this study hypothesizes that perioperative dxm infusion in patients undergoing major non-cardiac surgery with sevo anesthesia will reduce the incidence and severity of po-aki, especially in those with pre-existing or borderline renal dysfunction.


Eligibility criteria:
inclusion criteria: * patients who were assigned for tkr surgery; * patients with preoperative serum creatinine (scr) levels of \<1.1 mg/ml; * patients with controlled medical conditions; * patients free of exclusion criteria were enrolled in the study. exclusion criteria: * male patients were excluded to guard against the impact of senile prostatic hypertrophy on kidney functions; * patients who had preoperative scr of \>1.1 mg/dl; * presence of any urological disorders, urological stone diseases; * patients with autoimmune diseases, medical disorders requiring maintenance on immunosuppressant therapy; * patients with cancer anywhere in the body were excluded.
study of enfuvirtide in hiv-positive subjects

Conditions: HIV Infections; AIDS

Summary: a total of 26 patients will be admitted to the clinic where they will be dosed with each injection device. there will be a 7-day washout between doses and a 7-10 day follow-up period.


Eligibility criteria:
inclusion criteria: - exclusion criteria: -
topical oestrogens and antimuscarinics in the treatment of detrusor overactivity

Conditions: Overactive Bladder

Summary: despite the great number of reports about the efficacy of oestrogens or antimuscarinics on oab symptoms, so far no author has tried to investigate whether the concomitant administration of these two drugs, acting on two different pathophysiological mechanisms, could have a synergic effect reducing the rate of non-responders to treatment.


Eligibility criteria:
inclusion criteria: * all post-menopausal women with symptoms of overactive bladder and urodynamically proven pure detrusor overactivity exclusion criteria: * concomitant urodynamic stress incontinence * documented recurrent urinary tract infections * previous antimuscarinic treatment * previous pelvic surgery * concomitant systemic hrt * history of breast or endometrial cancer * neurological disease * clinical contraindications to treatment with oestrogen or antimuscarinics * patients included in other ongoing clinical trials
effect of fish oil on surgery pain after knee replacement patients: randomized, prospective, double blind, placebo control trial

Conditions: Rheumatoid Arthritis

Summary: this is a single-center, prospective, randomized, double blind, placebo control study. the aim of this study is to assess the effect of fish oil capsules on pain intensity and postoperative analgesics consumption in patients after knee replacement surgery. the study population will be adult are referred for knee replacement surgery due to osteoarthritis of the knee.

primary outcome: post surgical pain level and analgesics use secondary outcomes: 1. pain levels and analgesic use at six weeks and 3 months after surgery 2. ω3 incorporation into blood cell membranes(rbc) 3. stress and inflammation markers 4. rates of postoperative complications study procedure : enrolled patient will be randomly divided into a control group and intеrvention group during preoperative clinic visit. each patient will receive total 150 capsules (5 capsules per day) accordingly to randomized group. patients in treatment group will receive fish oil capsules. patients in control group will receive placebo capsules.

Eligibility criteria:
inclusion criteria: patients are referred for knee replacement surgery due to osteoarthritis of the knee * exclusion criteria: * use of steroids, nsaids two weeks before surgery, antidepression drugs, antiepileptic drugs, coumadin * diabetic neuropathy * herpes-zoster/ post-herpetic neuralgia * n-3 supplements use

Keywords: fish oil knee analgetics
a clinical randomized controlled trial of the new method of selective coronary vein bypass graft (scvbg)

Conditions: Coronary Atherosclerotic Heart Disease

Summary: apply a new operation method of left internal mammary artery (lima)-greater saphenous vein (gsv)-scvbg to the treatment of patients with diffuse coronary artery disease,through clinical randomized controlled study,compared with patients of bilateral internal mammary artery (bima)-scvbg and evaluate both of therapeutic effects and prognosis.


Eligibility criteria:
inclusion criteria: * patients with right coronary artery diffuse lesions:right coronary artery lumen≤1mm，lesion lengths ≥20mm or multiple segment lesions. * patients of coronary artery bypass grafting (cabg) that can't be treated through endarterectomy. * patients ≤ 70 years old. * all enrolled patients must being signed the informed consent. exclusion criteria: * severe heart failure(ejection fraction under 35%) or non coronary atherosclerotic heart disease patients such as combined with severe valvular heart disease. * patients with acute myocardial infarction. * assistant examinations indicate that the bridge vessels can't be used；the left subclavian artery stenosis and/or lima lesions；rima lesions；varicosis of both great saphenous vein.
hbv-specific tcr-t cell therapy combined with nucleos(t)ide analogues in chronic hepatitis b patients

Conditions: Chronic Hepatitis B

Summary: this is a open-label study to evaluate the safety and efficacy of autologous t-cells transfected with messenger ribonucleic acid (mrna) encoding hepatitis-b virus (hbv) antigen specific t cell receptor (tcr) in combination with nucleos(t)ide analogues (nas) in hbeag-positive chronic hepatitis b patients.


Eligibility criteria:
inclusion criteria: * chb infection (serum hbsag-positive for ≥ 6 months) * serum hbeag-positive * hla class 1 profile matching hla-class i restriction element of the available t cell receptors (restricted by either hla-a\*02:01, a\*11:01 or a\*24:02). * liver biopsy, fibroscan or equivalent test obtained within the past 6 months demonstrating liver disease consistent with chronic hbv infection without evidence of bridging fibrosis or cirrhosis (≥metavir 3). exclusion criteria: * history or other evidence of chronic liver disease unrelated to hbv infection (e.g., hemochromatosis, autoimmune hepatitis, alcoholic liver disease, toxin exposure, thalassemia, non-alcoholic fatty liver disease) * decompensated liver function, such as child-pugh grade b or c, or clinical signs of decompensated liver function like ascites and varices * positive hiv test result * history or suspected diagnosis of hepatocellular carcinoma, or afp at screening \> 20 ng/ml (if afp \> 20 ng/ml, a liver scan result is required to exclude hepatocellular carcinoma)
study of us-atg-f to prevent chronic graft versus host disease (gvhd)

Conditions: GVHD; Adult Acute Myeloid Leukemia; Adult Acute Lymphoid Leukemia; Myelodysplastic Syndrome

Summary: the study objective is to compare the efficacy and safety of us-atg-f as a supplement to standard of care prophylaxis versus standard of care prophylaxis alone in moderate to severe chronic gvhd-free survival.

this study is randomized, prospective, double-blind, placebo-controlled, phase 3 study evaluating the prevention of moderate to severe chronic gvhd in patients undergoing bone marrow or peripheral blood stem cell transplantation from matched, unrelated donors for acute leukemia and myelodysplastic syndrome during the first year after transplant. patients meeting all the inclusion and none of the exclusion criteria will be randomized (1:1). all patients will receive premedication and study drug 3 days prior to transplantation.

Eligibility criteria:
key inclusion criteria: * patients designated to undergo allogeneic peripheral blood or bone marrow stem cell transplantation following the diagnosis of one of the primary diseases in early or intermediate disease status (i.e., acute myeloid leukemia, acute lymphoid leukemia, and myelodysplastic syndrome) * patients with an unrelated hla-a,-b, -c and -drbi matched donor * patients with a karnofsky performance score ≥ 70% key exclusion criteria: * clinically significant concomitant diseases (i.e., cardiac, pulmonary, renal and cns) * bacterial, viral, or fungal infections * known positive for hepatitis b surfaces antigen, or hepatitis c antibody, or who have been tested positive for hiv * patients with any concurrent malignancy. cancer treated with curative intent \< 5 years previously will not be allowed except for patients with resected basal cell carcinoma or treated cervical carcinoma in situ * known contraindications to the administration of rabbit immunoglobulin antibodies * hypersensitivity to methylprednisolone, tacrolimus, methotrexate or any excipients contains in these products

Keywords: adult acute myeloid leukemia adult acute lymphoid leukemia adult myelodysplastic syndrome allogenic stem cell transplantation unrelated donor gvhd us-atg-f (anti-human-t-lymphocyte immune globulin, rabbit)
testing pulse stimulation to improve motor function in people with als: a pilot study

Conditions: Amyotrophic Lateral Sclerosis (ALS)

Summary: the goal of this clinical trial is to assess the efficacy of tps of the motor cortex on biomarkers and clinical endpoints in patients with als. the main questions it aims to answer are: * stage 1: is there a change in the short intracortical inhibition (sici) of the motor cortex from baseline to week 8? * stage 2: is there a change from baseline to month 6 in the als functional rating scale-revised (alsfrs-r) total score? in stage 2, researchers will compare the group receiving the stimulation vs the group receiving a sham stimulation to see if there is a difference in motor cortex activity and in the alsfrs-r score participants will receive either: * the tps treatment * a sham tps treatment


Eligibility criteria:
inclusion criteria: * patients with diagnosis of sporadic als (definite or clinically probable) as defined by the world federation of neurology revised el escorial criteria * svc of 50% or greater of estimated measure and presence of measurable motor evoked potential * 21 to 80 years old and male or female exclusion criteria: * patients with fals (based on medical history) that are unable to tolerate tms and mri studies or have a contraindication as described below

Keywords: transcranial pulse stimulation (tps) amyotrophic lateral sclerosis (als)
milk as treatment for hypoglycemia

Conditions: Type 1 Diabetes

Summary: test hypothesis that milk can raise blood sugars as well as orange juice or glucose tablets without raising blood sugars too much the way that orange juice or glucose tablets sometimes do.

subjects will wear a continuous glucose monitor prior to test to determine normal glucose levels. the morning of the test an iv will be inserted into the subject and insulin and saline drips will be started. blood glucose levels will be checked every 10 minutes until the subject becomes hypoglycemic. ivs will be stopped at that time and subject will be given skim milk, orange juice or glucose tablets at that time. blood will be drawn every 15 minutes until blood sugars stabilize. blood draws will be analyzed to determine glucose, insulin, epinephrine, norepinephrine, glucagon, cortisol, growth hormone and glp-1 levels. procedure will be repeated two more times using other glucose methods (skim milk, orange juice or glucose tablets).

Eligibility criteria:
inclusion criteria: * type 1 diabetes * able to be consented * able to wear continuous glucose monitor

Keywords: hypoglycemia